Correlation Engine 2.0
Clear Search sequence regions


  • absorb (3)
  • cohort (1)
  • death (2)
  • mace (2)
  • patients (6)
  • registry (4)
  • thrombosis (2)
  • vessel (3)
  • Sizes of these terms reflect their relevance to your search.

    To analyze procedural results and mid-term safety of everolimus-eluting bioresorbable vascular scaffolds (BVS) used for percutaneous coronary intervention in a large all-comer cohort from the German-Austrian ABSORB Registry (GABI-R). A total of 3231 patients were included in this prospective, observational, multicentre study (Clinicaltrial.gov NCT02066623) of consecutive patients undergoing BVS implantation between November 2013 and January 2016. Endpoints were major adverse cardiac events (MACE, a composite endpoint of death, target vessel revascularization, and myocardial infarction) and target lesion failure (TLF), a composite endpoint of cardiac death, target vessel myocardial infaction, and target lesion revascularization). Scaffold thrombosis was a further endpoint. Of all patients, 51.5% presented with acute coronary syndrome. Pre-dilatation and post-dilatation were performed in 91.5% and 71.9% of patients. Procedural success was 98.9%. After 6 months, the incidence of MACE was 4.1% and of TLF 2.4%. The rate of target vessel MI was 1.5%, and target lesion revascularization was performed in 1.8%. Definite/ probable scaffold thrombosis was documented in 1.4% of patients. GABI-R, the largest registry to provide data regarding safety after BVS implantation in a real-world setting, reveals high procedural success and low 6-month event rates.

    Citation

    Holger M Nef, Jens Wiebe, Johannes Kastner, Julinda Mehilli, Thomas Münzel, Christoph Naber, Till Neumann, Gert Richardt, Axel Schmermund, Jochen Wöhrle, Ralf Zahn, Thomas Riemer, Stephan Achenbach, Christian W Hamm. Everolimus-eluting Bioresorbable Scaffolds in Patients with Coronary Artery Disease: Results from the German-Austrian ABSORB RegIstRy (GABI-R). EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2017 Aug 22


    PMID: 28829745

    View Full Text